Q4 2022 Medivir AB Earnings Call Transcript
Welcome everyone to our quarterly call. And operator, if we move to the next slide, slide 2, please.
So joining me in the room here at Medivir is our CFO, Magnus Christensen, who will go through the financial highlights towards the end of the call . And our CSO, Fredrik Ãberg, who will take the science section of the call in the middle. And with that, let's jump into sort of the agenda for today. So operator, if we move two slides ahead -- or actually three slides ahead to slide 5, please.
Highlights during last quarter. I think with 2022 was a year of sort of moving our lead project fostrox forward with as much speed as we possibly could. And Q4 was sort of clearly on the same focus. We are quite happy with the continued strong recruitment we've seen in the fostrox study, and we're now eagerly anticipating sort of moving to the next phase in the near term to set the recommended Phase 2 dose. And we're very encouraged with the interest we've seen in the study in terms of recruiting patients into both of the combination arms.
During Q4, we had an
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
